Tech Company Financing Transactions
TauRx Pharmaceuticals Funding Round
Private investors participated in a $119 million funding round for TauRx Pharmaceuticals. The round closed on 11/14/2022.
Transaction Overview
Company Name
Announced On
11/14/2022
Transaction Type
Venture Equity
Amount
$119,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate development plans for regulatory approval in China.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3 Shenton Way 21-04
Singapore City, 068805
Singapore
Singapore City, 068805
Singapore
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
TauRx Pharmaceuticals Ltd is a spin-out company from the University of Aberdeen, Scotland, and was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Claude Wischik
Chief Operating Officer
Timothy Earle
Chief Scientific Officer
Charles Harrington
Chief Technical Officer
John Storey
VP - Finance
Hwang Wei
Browse more venture capital transactions:
Prev: 11/14/2022: Impact venture capital transaction
Next: 11/14/2022: Spark venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs